AMAG Pharmaceuticals, Inc. to Present at the 31st Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass.–(BUSINESS WIRE)–Dec. 26, 2012–
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William
Heiden, AMAG’s chief executive officer, will present at the 31^st
Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013
at 8:30 am Pacific Time. The presentation will include a company
overview and business update.

A live webcast of the presentation will be accessible through the
Investors section of the company’s website at www.amagpharma.com.
Following the conference, the webcast will be archived on the AMAG
Pharmaceuticals, Inc. website until February 9, 2013.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that
manufactures and markets Feraheme® (ferumoxytol) Injection for
Intravenous (IV) use in the United States. Along with driving organic
growth of its lead product, AMAG intends to expand its portfolio with
additional commercial-stage specialty pharmaceuticals. The company is
seeking complementary products that leverage the company’s commercial
footprint and focus on hematology and oncology centers and hospital
infusion centers. For additional company information, please visit www.amagpharma.com.

Source: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303